A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 25, 2015

Primary Completion Date

February 8, 2016

Study Completion Date

February 8, 2016

Conditions
AsthmaEfficacySafety
Interventions
DRUG

800 μg AZD7594 once daily

Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule

DRUG

250 µg AZD7594 once daily

Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule

DRUG

58 µg AZD7594 once daily

Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule

DRUG

Placebo once daily

Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule

DRUG

Salbutamol

Inhalation as needed

Trial Locations (10)

1612

Research Site, Sofia

10717

Research Site, Berlin

10969

Research Site, Berlin

14050

Research Site, Berlin

20354

Research Site, Hamburg

22143

Research Site, Hamburg

22927

Research Site, Großhansdorf

23552

Research Site, Lübeck

60596

Research Site, Frankfurt

65187

Research Site, Wiesbaden

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY